WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206483
CAS#: 1239875-86-5
Description: SGI-7079 is a potent and selective Axl inhibitor with potential anticancer activity. SGI-7079 effectively inhibited Axl activation in the presence of exogenous Gas6 ligand. SGI-7079 inhibited tumor growth in a dose dependent manner. Axl is a potential therapeutic target for overcoming EGFR inhibitor resistance.
MedKoo Cat#: 206483
Name: SGI-7079
CAS#: 1239875-86-5
Chemical Formula: C26H26FN7
Exact Mass: 455.22337
Molecular Weight: 455.5414
Elemental Analysis: C, 68.55; H, 5.75; F, 4.17; N, 21.52
SGI-7079, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).
Synonym: SGI-7079; SGI 7079; SGI7079.
IUPAC/Chemical Name: 2-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetonitrile
InChi Key: BCFKACXAIBEPKR-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H26FN7/c1-17-16-29-25-23(17)24(19-5-3-4-18(14-19)8-9-28)31-26(32-25)30-20-6-7-22(21(27)15-20)34-12-10-33(2)11-13-34/h3-7,14-16H,8,10-13H2,1-2H3,(H2,29,30,31,32)
SMILES Code: N#CCC1=CC=CC(C2=C3C(NC=C3C)=NC(NC4=CC=C(N5CCN(C)CC5)C(F)=C4)=N2)=C1
The following data is based on the product molecular weight 455.5414 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM,
Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 promotes the
development and progression of inflammatory breast cancer through activation of
Axl kinase. Cancer Res. 2013 Nov 1;73(21):6516-25. doi:
10.1158/0008-5472.CAN-13-0967. Epub 2013 Sep 6. PubMed PMID: 24014597.
2: Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri
U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL,
Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS,
Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN,
Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal
transition gene signature predicts resistance to EGFR and PI3K inhibitors and
identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558.
Epub 2012 Oct 22. PubMed PMID: 23091115; PubMed Central PMCID: PMC3567921.